疾病监测与控制2024，Vol.20Issue(3)：176-179,197,5.DOI:10.19891/j.issn1673-9388.(2024)03-0176-05
止吐药物与质子泵抑制剂临床药学路径的应用效果分析
CLINICAL PHARMACY PATHWAY ANALYSIS OF ANTIEMETIC DRUGS AND PROTON PUMP INHIBITORS
摘要
Abstract
Objective To analyze the clinical pharmacy pathway effect of antiemetic drugs and proton pump inhibitors.Methods The study period was from January 2022 to February 2023,and a total of 300 cancer patients admitted to the Depart-ment of Oncology in our hospital were enrolled as the study objects.From January 2022 to July 2022,antiemetic drugs and proton pump inhibitors were used as routine interventions,and 150 patients were enrolled in the study.From August 2022 to February 2023,the clinical pharmacy pathway approach was applied to antiemetic drugs and proton pump inhibitors,and 150 patients were enrolled in the study,setting the group name after implementation.The effect of intervention in the two groups was analyzed.Re-sults After the implementation of antiemetic drugs and proton pump inhibitors per capita drug cost,sales amount,use intensity,frequency statistics were lower than before the implementation(P＜0.05);The incidence of irrational drug use and adverse reac-tions were lower after implementation than before implementation(P＜0.05).Before implementation,the majority of patients had moderate adverse reactions,but after implementation,the majority of patients had mild adverse reactions(P＜0.05).In terms of quality of life,the scores of physiological function,physiological function,general health,mental health,vitality,physical pain,emotional function and social function were higher after implementation than before implementation,and the data were different(P＜0.05).Conclusion Through clinical pharmacy pathway,it is helpful to improve the rational drug use effect of antiemetic drugs and proton pump inhibitors,and the adverse reactions of patients are less and the severity is less.关键词
临床药学路径/止吐药物/质子泵抑制剂/多拉司琼/雷贝拉唑/不良反应Key words
clinical pharmacy pathway/antiemetic drugs/proton pump inhibitors/dorasetron/rabeprazole/adverse reac-tion分类
医药卫生引用本文复制引用
徐军华,罗艳萍,陈清智..止吐药物与质子泵抑制剂临床药学路径的应用效果分析[J].疾病监测与控制,2024,20(3):176-179,197,5.基金项目
龙岩市科技计划项目(FLY2022CWS010121) （FLY2022CWS010121）
